Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Rosiglitazone and cardiotoxicity--weighing the evidence.

Nathan DM.

N Engl J Med. 2007 Jul 5;357(1):64-6. Epub 2007 Jun 5. No abstract available.

2.

[Rosiglitazone: clinical data].

Blickle JF.

Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 2):1S27-33. Review. French. No abstract available.

PMID:
12037505
3.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
4.

Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.

Garber AJ.

Diabetes Obes Metab. 2000 Jun;2(3):139-47. Review. No abstract available.

PMID:
11220549
5.

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association.

Circulation. 2003 Dec 9;108(23):2941-8. Review. No abstract available.

6.

Rosiglitazone and cardiovascular risk: weighing recent evidence.

Stafylas PC, Sarafidis PA, Lasaridis AN.

J Cardiometab Syndr. 2007 Fall;2(4):295-6. Review. No abstract available.

7.

Thiazolidinedione derivatives in type 2 diabetes mellitus.

Tack CJ, Smits P.

Neth J Med. 2006 Jun;64(6):166-74. Review.

8.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
9.

Treating type 2 diabetes: targeting the many causative factors.

Sutherland JE, Hoehns JD.

J Fam Pract. 2004 May;53(5):376-88. Review. No abstract available.

PMID:
15125823
10.

[Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].

De Flines J, Scheen AJ.

Rev Med Suisse. 2007 Aug 29;3(122):1876, 1878-83. Review. French.

PMID:
17896661
11.

[Heart failure with thiazolidinedione treatment: what do we know today?].

Erdmann E.

Dtsch Med Wochenschr. 2009 Jan;134(4):154-8. doi: 10.1055/s-0028-1123973. Epub 2009 Jan 15. Review. German.

PMID:
19148858
12.

The use of insulin secretagogues in the treatment of type 2 diabetes.

Luna B, Hughes AT, Feinglos MN.

Prim Care. 1999 Dec;26(4):895-915. Review.

PMID:
10523467
13.

Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

Beale S, Bagust A, Shearer AT, Martin A, Hulme L.

Pharmacoeconomics. 2006;24 Suppl 1:21-34. Review.

PMID:
16800160
14.

Do thiazolidinediones cause heart failure? A critical review.

Tang WH.

Cleve Clin J Med. 2006 Apr;73(4):390-7. Review. Erratum in: Cleve Clin J Med. 2006 Jun;73(6):588.

PMID:
16610400
15.

Metformin.

Bailey CJ, Turner RC.

N Engl J Med. 1996 Feb 29;334(9):574-9. Review. No abstract available.

PMID:
8569826
16.

[Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].

Hemmingsen B, Lund SS, Vaag A.

Ugeskr Laeger. 2009 May 4;171(19):1598-602. Review. Danish.

PMID:
19419642
17.

Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.

Setter SM, Iltz JL, Thams J, Campbell RK.

Clin Ther. 2003 Dec;25(12):2991-3026. Review.

PMID:
14749143
18.

Role of metformin in type II diabetes.

Epstein S.

Cleve Clin J Med. 1995 Sep-Oct;62(5):278-9. Review. No abstract available.

PMID:
7586481
19.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
20.

The "glitazones": rosiglitazone and pioglitazone.

Papoushek C.

J Obstet Gynaecol Can. 2003 Oct;25(10):853-7. Review. Erratum in: J Obstet Gynaecol Can. 2003 Nov;25(11):907.

PMID:
14532954
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk